ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

First Page		Document Content
Date: 2014-01-03 10:02:43 Denosumab Bisphosphonates Zoledronic acid Osteoporosis Multiple myeloma Osteonecrosis of the jaw Hypercalcaemia Management of cancer Renal cell carcinoma Medicine Health Amgen		ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS Add to Reading List Source URL: www.ema.europa.eu Download Document from Source Website File Size: 656,55 KB Share Document on Facebook

	POSTER SESSION 1: NEOPLASMS. VARIA. Exhibition area, 7 May, 09.00 – 12.00 h Chairperson: Radko Radev (Varna), Secretary: Vessela Uzunova (Sofia) 1. The therapy of the advanced renal cell carcinoma – new agents and st DocID: 1uMwb - View Document
	Assessment RunPAX8 Material The slide to be stained for PAX8 comprised: 1. Fallopian tube, 2. Tonsil, 3. Kidney, 4. Renal clear cell carcinoma, DocID: 1uiGA - View Document
	· RENAL CELL CARCINOMA · Biomarkers for Renal Cell and Urothelial Carcinoma Nazli Dizman, MD, Joann Hsu, BS, Paulo Bergerot, MD, Manuel Caitano Maia, MD, and Sumanta K. Pal, MD Keywords: Biomarkers, renal cell carcin DocID: 1sTBk - View Document
	www.edoriumjournals.com CASE REPORT PEER REVIEWED \| OPEN ACCESS DocID: 1qNSk - View Document
	sorafenib clinical trial risks of sorafenib sorafenib gastric cancer. sorafenib agent sorafenib pulmonary risks sorafenib lung cancer sorafenib dosage DocID: 1qmZp - View Document